Pay in 4 interest-free payments of $6.36 Learn more
Ships within 48 hours · Estimated delivery Sep 2 - Sep 7
2019;5(7):e02162
Patients with commercial insurance also face strict eligibility criteria
RGN-352 is RegeneRx Biopharmaceuticals' injectable Thymosin Beta-4 formulation developed for cardiac repair and systemic tissue damage
On the heels of As of Monday January 5, 2026, patients will have access to the starter dose of the oral GLP-1, 1.5 mg, with additional strengths reported to be released by the end of the week
Reassess around week 12 at your target dose
US$ 25.20
US$ 27.65
US$ 26.53
US$ 22.67
US$ 25.99
US$ 26.39
US$ 20.39
US$ 29.91
US$ 29.40
US$ 21.52
